Targeting TYK2 in Cutaneous Autoimmunity: Deucravacitinib-Induced Remission of Discoid Lupus and Psoriasis with Supportive Confocal Microscopy Findings

Key Points

• The aim is to evaluate the effectiveness of deucravacitinib in treating refractory discoid lupus and concomitant psoriasis.
• Observed the effects of deucravacitinib on patients with refractory discoid lupus and psoriasis.
• Utilized confocal microscopy to support findings.
• Monitored clinical outcomes and remission rates during treatment.
• Deucravacitinib showed significant improvement in discoid lupus symptoms.
• Patients experienced remission of psoriasis alongside lupus treatment.
• Confocal microscopy findings supported the therapeutic effects observed.